Scabies and thérapeutic resistance: Current knowledge and future perspectives

[en] Scabies is a very common ectoparasitosis and is responsible for a real scourgeworldwide. The infestation leads to a highly contagious and pruritic dermatosis.Clinical diagnosis is not always easy; dermoscopy is a very useful diagnostic tool.Treatment relies on hygienic measures and specific acaricidals, either for topicalapplication or oral administration. Ivermectin, permethrin and benzyl benzoateare the most frequently used therapies. Treatment failure is on the rise and couldbe attributed to noncompliance, treatment costs or to resistance to these agents. A series of novel agents are currently under investigation.

Disciplines :

Dermatology

Author, co-author :

Absil, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Lebas, Eve ; Université de Liège - ULiège > Département des sciences cliniques

Libon, Florence ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

El Hayderi, Lara ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Dezfoulian, Bita ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie

Nikkels, Arjen ; Université de Liège - ULiège > Département des sciences cliniques > Dermatologie

Language :

English

Title :

Scabies and thérapeutic resistance: Current knowledge and future perspectives

Publication date :

April 2022

Journal title :

Journal of the European Academy of Dermatology and Venereology

ISSN :

0926-9959

eISSN :

1468-3083

Publisher :

Wiley, Oxford, United Kingdom

Available on ORBi :

since 01 March 2023

Statistics

Number of views

87 (9 by ULiège)

Number of downloads

7 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Karimkhani C, Colombara DV, Drucker AM, Norton SA, Hay R, Engelman D, et al. The global burden of scabies: a cross-section analysis from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17:1247–54.
Sunderkötter C, Aebischer A, Neufeld M, Löser C, Kreuter A, Bialek R, et al. Increase of scabies in Germany and development of resistant mites? Evidence and consequences. J Dtsch Dermatol Ges. 2019;17:15–23.
Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guidelines for the management of scabies. J Eur Acad Dermatol Venereol. 2017;31:1248–53.
Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, et al. The 2020 international alliance for the control of scabies consensus criteria for the diagnosis of scabies. Br J Dermatol. 2020;183(183):808–20.
Cassel JA, Middleton J, Nalabanda A, Lanza S, Head MG, Bostock J. Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes. Lancet Infect Dis. 2018;18:894–902.
Bhat SA, Mounsey KE, Liu X, Walton SF. Host immune responses to the itch mite, Sarcoptes scabiei, in humans. Parasit Vectors. 2017;10:385.
Argenziano G, Fabbrocini G, Delfino M. Epiluminescence microscopy. A new approach to in vivo detection of Sarcoptes scabiei. Arch Dermatol. 1997;133:751–3.
Engelman D, Kiang K, Chosidow O, McCarthy J, Fuller C, Lammie P, et al. Toward the global control of human scabies: introducing the international alliance for the control of scabies. PLoS Negl Trop Dis. 2013;7:e2167.
Swe PM, Fischer K. A scabies mite serpin interferes with complement-mediated neutrophil functions and promotes staphylococcal growth. PLoS Negl Trop Dis. 2014;8:e2928.
Chung SD, Wang KH. Increased risk of pemphigoid following scabies: a population-based matched-cohort study. J Eur Acad Dermatol Venereol. 2014;28:558–64.
Victoria J, Trujillo R. Topical ivermectin: a new successful treatment for scabies. Pediatr Dermatol. 2001;18:63–5.
Amerio P, Capizzi R, Milani M. Efficacy and tolerability of natural synergised pyrethrins in a new thermo labile foam formulation in topical treatment of scabies: a prospective, randomised, investigator-blinded, comparative trial vs. Permethrin cream. Eur J Dermatol. 2003;13:69–71.
Bernigaud C, Fernando DD, Lu H, Taylor S, Hartel G, Chosidow O, et al. How to eliminate scabies from fomites: a high-throughout ex vivo experimental study. J Am Acad Dermatol. 2020;83(1):241–245.
Arora P, Rudnicka L, Sar-Pomian M. Scabies: a comprehensive review and current perspectives. Dermatol Ther. 2020;33:e13746.
Qian G, Hou L, Guo W. A fussy infant with a generalized papulovesicular rash. JAMA. 2019;321:604–5.
Levy M, Martin L, Bursztein AC, Chiaverini C, Miquel J, Mahé E, et al. Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study. Br J Dermatol. 2020;182:1003–6.
Jittamala P, Monteiro W, Smit MR, Pedrique B, Specht S, Chaccour CJ, et al. A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: is it time to reconsider the current contraindication?PLoS Negl Trop Dis. 2021;15:e0009144.
Walker SL, Head MG, Middleton J, Cassel JA. Ivermectin in the management of a scabies outbreak in a long-term care facility. Br J Dermatol. 2021;185:868.
Centre de Référence sur les Agents Tératogènes (CRAT). Paris (FR): Ivermectine—Grossesse et allaitement. https://lecrat.fr/spip.php?page=article%26id_article=576 (2020).
Morrison EJ, Middleton J, Lanza S, Cowen JE, Hewitt K, Walker SL, et al. Do we know how scabies in resident nursing care homes for the elderly should be managed? A systematic review of interventions using a novel approach to assess evidence quality. Epidemiol Infect. 2019;147:e250.
Khalil S, Abbas O, Kibbi AG, Kurban M. Scabies in the age of increasing drug resistance. PLoS Negl Trop Dis. 2017;11:e0005920.
Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies endemic communities. Arch Dermatol. 2009;145:840–1.
Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis. 2004;39:e8–12.
Mounsey KE, Pasay CJ, Arlian LG, Morgan MS, Holt DC, Currie JB, et al. Increased transcription of Glutathione S-transferases in acaricide exposed scabies mites. Parasit Vectors. 2010;18:43.
Pasay C, Arlian L, Morgan M, Gunning R, Rossiter L, Holt D, et al. The effect of insecticide synergists on the response of scabies mites to pyrethroid acaricides. PLoS Negl Trop Dis. 2009;3:e354.
Bakkali F, Averbeck S, Averbeck D, Idaomar M. Biologicals effects of essential oils—a review. Food Chem Toxicol. 2008;46:446–75.
Thomas J, Davey R, Peterson GM, Carson C, Walton SF, Spelman T, et al. Treatment of scabies using a tea tree oil-based gel formulation in Australian Aboriginal children: protocol for a randomised controlled trial. BMJ Open. 2018;31(8):e018507.
Walton SF, Mckinnon M, Pizzutto S, Dougall A, Williams E, Currie BJ. Acaricidal activity of Melaleuca alternifolia (tea tree) oil: in vitro sensitivity of scabiei var hominis to terpinen-4-ol. Arch Dermatol. 2004;140:563–6.
De Groot A, Schmidt E. Tea tree oil: contact allergy and chemical composition. Contact Dermatitis. 2016;75:129–43.
Oladimeji FA, Orafidiya OO, Oguaniyi TAB, Adewunmi TA. Pediculocidal and scabicidal properties of Lippia multiflora essential oil. J Ethnopharmacol. 2000;72:305–11.
Fang F, Candy K, Melloul E, Bernigaud C, Chai L, Darmon C, et al. In vitro activity of ten essential oils against Sarcoptes scabiei. Parasit Vectors. 2016;9:594.
Li M, Liu S, Yin Z, Bernigaud C, Guillot J, Fang F. Activity of terpenes derived from essential oils against Sarcoptes scabiei eggs. Parasit Vectors. 2021;14:600.
Mounsey KE, Shelly SF, Innes A, Cash-Deans S, McCarthy JS. In vitro efficacy of moxidectin versus ivermectin against Sarcoptes scabiei. Antimicrob Agents Chemother. 2017;61:e00381–17.
Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, et al. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet 2018;392:1207–16.
Seiler JC, Keech RC, Aker JL, Miller W, Belcher C, Mettert KW. Spinosad at 0,9% in the treatment of scabies: efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies. J Am Acad Dermatol. 2022;86:97–103.
Bernigaud C, Fang F, Fischer K, Lespine A, Aho LS, Mullins AJ, et al. Efficacy and pharmacokinetics evaluation of a single oral dose of afoxolaner against Sarcoptes scabiei in the porcine scabies model for human infestation. Antimicrob Agents Chemother. 2018;62:e02334–17.
Pasay C, Rothwell J, Mounsey K, Kelly A, Hutchinson B, Miezler A, et al. An exploratory study to assess the activity of the acarine growth inhibitor, fluazuron, against Sarcoptes scabei infestation in pigs. Parasit Vectors. 2012;5:40.
Holt DC, Fischer K, Allen GE, Wilson D, Wilson P, Slade R, et al. Mechanisms for a novel immune evasion strategy in the scabies mite Sarcoptes scabiei: a multigene family of inactivated serine proteases. J Invest Dermatol 2003;121:1419–24.
Gu X, Xie Y, Wang S, Peng X, Lai S, Yang G. Immune response induced by candidate Sarcoptes scabiei var. cuniculi DNA vaccine encoding paramyosin in mice. Exp Appl Acarol. 2014;63:401–12.
Walton SF. The immunology of susceptibility and resistance to scabies. Parasit Immunol. 2010;32:532–40.
Fernando DD, Marr EJ, Zakrzewski M, Reynolds SL, Burgess STG, Fischer K. Gene silencing by RNA interference in Sarcoptes scabiei: a molecular tool to identify novel therapeutic targets. Parasit Vectors. 2017;10:289.